3-(4-乙氧基苯基)丙酸 | 4919-34-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: 3-(4-乙氧基苯基)丙酸
• 中文别名: 3-(4-乙氧苯基)丙酸
• 英文名称: p-ethoxybenzenepropanoic acid
• 英文别名: 3-<4-Aethoxy-phenyl>-propionsaeure；3-<4-Aethyloxy-phenyl>-propionsaeure；4-Aethoxyphenyl-propionsaeure；β-(p-Aethoxyphenyl)-propionsaeure；β-(4-Aethoxy-phenyl)-propionsaeure；3-(4-Aethoxy-phenyl)-propionsaeure；3-(4-ethoxy-phenyl)-propionic acid；Aethylaether-hydro-p-cumarsaeure；3-(4-Ethoxyphenyl)propanoic acid
• CAS: 4919-34-0
• 化学式: C₁₁H₁₄O₃
• mdl: MFCD00016557
• 分子量: 194.23
• InChiKey: ZDSHOEQSCJOGCK-UHFFFAOYSA-N

物化性质

• 熔点：
  102-104°C
• 沸点：
  331.6±17.0 °C(Predicted)
• 密度：
  1.116±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  在常温常压下，该物质保持稳定。

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2918990090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(4-Ethoxyphenyl)propanoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(4-Ethoxyphenyl)propanoic acid
CAS number: 4919-34-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H14O3
Molecular weight: 194.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(4-乙氧基苯基)丙酸 在 铬酸 作用下， 生成 对乙氧基苯甲酸
  参考文献：
  名称：

  Koerner; Corbetta, Chemische Berichte, 1874, vol. 7, p. 1736

  摘要：

  DOI：
• 作为产物：
  描述：

  4-ethoxycinnamic acid 在 钯 作用下， 以 四氢呋喃 为溶剂， 生成 3-(4-乙氧基苯基)丙酸
  参考文献：
  名称：

  Novel process to prepare 2-aminoindan derivatives

  摘要：

  本发明涉及公式I的2-氨基茚衍生物的(2S)-对映体1，以及它们的一种新的制备方法。

  公开号：

  US20020151596A1

文献信息

• Novel process to prepare 2-aminoindan derivatives
  申请人：——

  公开号：US20010044471A1

  公开（公告）日：2001-11-22

  The present invention relates to (2S)-enantiomers of 2-aminoindan derivatives of formula I: 1 and a novel process for the preparation of them.

  本发明涉及公式I中的(2S)-对映体的2-氨基茚衍生物，以及它们的一种新的制备方法。
• Quaternary ammonium antiarrhythmic drugs
  申请人：Eli Lilly and Company

  公开号：US04289787A1

  公开（公告）日：1981-09-15

  Quaternary ammonium salts of certain phenylbutylamines are useful antiarrhythmic drugs. A method for treating arrhythmia and prolonging the action potential of cardiac tissue is provided. Pharmaceutical formulations containing such quaternary ammonium salts are disclosed.

  某些苯丁胺的季铵盐是有用的抗心律失常药物。提供了一种治疗心律失常并延长心脏组织动作电位的方法。披露了含有这种季铵盐的药物配方。
• [EN] YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4<br/>[FR] INHIBITEURS DE YAP1 CIBLANT L'INTERACTION DE YAP1 AVEC OCT4
  申请人：H LEE MOFFITT CANCER CT & RES

  公开号：WO2018053446A1

  公开（公告）日：2018-03-22

  Binding of the transcriptional co-activator, YAP1, to the transcription factor Oct4, induces Sox2, which is a transcription actor necessary for the self-renewal of stem-like cells from non-small cell lung cancer. The WW domain of YAP1 binds to the PPxY motif of Oct4 to induce Sox2. Delivering a peptide corresponding to the WW domain could prevent the induction of Sox2 and stemness. Similarly, peptides and mimetics of the PPxY motif would be able to inhibit stemness. Disclosed are compounds that affect the Yap1:Oct4 interaction.

  转录共激活因子YAP1与转录因子Oct4的结合诱导Sox2，Sox2是非小细胞肺癌干细胞自我更新所必需的转录因子。YAP1的WW结构域与Oct4的PPxY基序结合以诱导Sox2。提供与WW结构域相对应的肽段可以阻止Sox2和干细胞特性的诱导。类似地，PPxY基序的肽段和模拟物能够抑制干细胞特性。揭示了影响Yap1:Oct4相互作用的化合物。
• [DE] 11 beta -HALOGEN-7 alpha -SUBSTITUIERTE-ESTRATRIENE, VERFAHREN ZUR HERSTELLUNG PHARMAZEUTISCHER PRÄPARATE, DIE DIESE 11 beta -HALOGEN-7 alpha -SUBSTITUIERTE-ESTRATRIENE ENTHALTEN, SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN<br/>[EN] 11 beta -HALOGEN-7 alpha -SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11 beta -HALOGEN-7 alpha -SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS<br/>[FR] ESTRATRIENES 11 beta -HALOGENE-7 alpha -SUBSTITUES, PROCEDE DE PREPARATION DE PREPARATIONS PHARMACEUTIQUES, QUI CONTIENNENT LESDITS ESTRATRIENES 11 beta -HALOGENE-7 alpha -SUBSTITUES ET LEUR UTILISATION POUR PREPARER DES MEDICAMENTS
  申请人：SCHERING AKTIENGESELLSCHAFT

  公开号：WO1999033855A1

  公开（公告）日：1999-07-08

  (DE) Die vorliegende Erfindung beschreibt die neuen 11$g(b)-Halogen-7$g(a)-substituierten-Estratriene der allgemeinen Formel (I), worin R11 ein Fluor- oder Chloratom ist und die anderen Substituenten die in der Beschreibung näher erläuterten Bedeutungen haben. Die Verbindungen verfügen über antiestrogene oder gewebeselektive estrogene Eigenschaften und sind zur Herstellung von Arzneimitteln geeignet.(EN) The invention relates to novel 11$g(b)-halogen-7$g(a)-substituted estratrienes of formula (I), wherein R11 is a fluorine or chlorine atom and the other substituents have the meanings given in the description. The inventive compounds have anti-estrogen or tissue selective estrogenic characteristics and are suitable for producing medicaments.(FR) L'invention concerne de nouveaux estratriènes 11$g(b)-halogène-7$g(a)-substitués de la formule générale (I) dans laquelle R11 désigne un atome de fluor ou de chlore et les autres substituants ont les significations mentionnées dans la description. Ces composés présentent des propriétés à action anti-oestrogène ou oestrogène à sélectivité tissulaire et s'utilisent pour préparer des médicaments.

  该发明涉及新的11$g(b)-卤素-7$g(a)-取代的Estratriene，其化学式为(I)，其中R11是氟或氯原子，其他取代基具有描述中所述的含义。这些化合物具有抗雌激素或组织选择性雌激素特性，适用于制备药物。
• Novel compounds
  申请人：——

  公开号：US20040116465A1

  公开（公告）日：2004-06-17

  Compounds of general formula (I), are disclosed and claimed in the present application, as well as salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain. 1

  本申请披露和声明一般式(I)的化合物，以及包括这些新化合物的盐和药物组合物，以及它们在治疗中的用途，特别是在疼痛管理方面。